Figure 4.
Figure 4. Dot plots demonstrating the correlation between the log reduction in BCR-ABL at 3 and 12 months after the start of imatinib therapy and IC50imatinib.

Dot plots demonstrating the correlation between the log reduction in BCR-ABL at 3 and 12 months after the start of imatinib therapy and IC50imatinib.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal